Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Trading 04-24 12:53:15 EDT

518.57

-0.17

-0.03%

High520.97	Low500.97	Vol87.59K
Open518.00	D1 Closing518.74	Amplitude3.85%
Mkt Cap11.90B	Tradable Cap5.70B	Total Shares22.94M
T/O44.94M	T/O Rate0.80%	Tradable Shares11.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":518.57,"timestamp":1777049588020,"preClose":518.74,"halted":0,"volume":87594,"delay":0,"changeRate":-0.0003277171608126597,"floatShares":11000087,"shares":22939969,"eps":-12.850138,"marketStatus":"Trading","change":-0.17,"latestTime":"04-24 12:53:15 EDT","open":518,"high":520.965,"low":500.97,"amount":44935384.7631,"amplitude":0.038545,"askPrice":519.01,"askSize":1,"bidPrice":517.79,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-12.850138,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777060800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":518.74,"preHourTrading":{"tag":"盘前","latestPrice":529.11,"preClose":518.74,"latestTime":"09:16 EDT","volume":24,"amount":12698.64,"timestamp":1777036612905,"change":10.37,"changeRate":0.019991,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":524.5,"preClose":518.74,"latestTime":"19:24 EDT","volume":71807,"amount":37249719.619,"timestamp":1776986670118,"change":5.76,"changeRate":0.011104,"amplitude":0.011566},"volumeRatio":0.60611,"impliedVol":0.6011,"impliedVolPercentile":0.6693},"requestUrl":"/m/hq/s/MDGL/tweets","defaultTab":"tweets","newsList":[{"id":"2629835534","title":"Ritu Baral Reaffirms Buy on Madrigal Pharmaceuticals Following Updated Financial Model and Sustained Long-Term Upside Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2629835534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629835534?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:15","pubTimestamp":1776942945,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/ritu-baral-reaffirms-buy-on-madrigal-pharmaceuticals-following-updated-financial-model-and-sustained-long-term-upside-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/ritu-baral-reaffirms-buy-on-madrigal-pharmaceuticals-following-updated-financial-model-and-sustained-long-term-upside-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","MDGL","XBI","XLV","BK4581","BK4588","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629045075","title":"Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629045075","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629045075?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:00","pubTimestamp":1776859200,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., April  22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278880/0/en/Madrigal-Pharmaceuticals-to-Release-First-Quarter-2026-Financial-Results-and-Host-Webcast-on-May-6-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","MDGL","BK4218","BK4181","HST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629503330","title":"Madrigal grants 5,758 inducement RSUs to 12 new employees under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2629503330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629503330?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:14","pubTimestamp":1776802468,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted 5,758 time-based restricted stock units to 12 new non-executive employees under its 2025 Inducement Plan.Equity awards were issued on April 1, 2026.Restricted stock units vest in four equal installments on first through fourth anniversaries of grant date.Vesting remains contingent on continued employment on each vesting date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL1QsMGk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629057743","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629057743","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629057743?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:05","pubTimestamp":1776801900,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., April  21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-asso","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278407/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626715850","title":"Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626715850","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626715850?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:32","pubTimestamp":1775766764,"startTime":"0","endTime":"0","summary":"Investors may be wondering if Madrigal Pharmaceuticals at around US$519.75 a share is still offering value, or if the easy gains are already behind it.\nThe stock has been volatile recently, with a 1.9% decline over the last week, a 20.0% return over 30 days, a 12.5% decline year to date, and a 65.6% return over the past year, alongside very large gains over 5 years.\nRecent headlines around Madrigal have focused on its position in the biotech space and the market's shifting expectations for...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/is-it-too-late-to-consider-madrigal-pharmaceuticals-mdgl-aft","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/is-it-too-late-to-consider-madrigal-pharmaceuticals-mdgl-aft","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4585","MDGL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625965128","title":"Madrigal grants 8,079 inducement RSUs to 20 new employees under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2625965128","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625965128?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:08","pubTimestamp":1775592484,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted inducement equity awards to 20 new non-executive employees on April 1, 2026.Awards totaled 8,079 time-based restricted stock units under Madrigal’s 2025 Inducement Plan.RSUs vest in four equal installments on each of first through fourth anniversaries of grant date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLbRcqjP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4139","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014039.USD","IE00BN0W2V16.EUR","MDGL","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","SG9999014005.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625966058","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625966058","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625966058?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:05","pubTimestamp":1775592300,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., April  07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-asso","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3269623/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622078608","title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Strength And Updated Fair Value Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078608","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078608?lang=en_us&edition=fundamental","pubTime":"2026-03-28 10:15","pubTimestamp":1774664109,"startTime":"0","endTime":"0","summary":"Event driven snapshot of Madrigal Pharmaceuticals\nMadrigal Pharmaceuticals (MDGL) has drawn investor attention after recent share price moves, including a 1 day return of about 2% and a 16% gain over the past week, against mixed month and past 3 months performance.\nSee our latest analysis for Madrigal Pharmaceuticals.\nThe recent 15.8% 7 day share price return contrasts with a weaker year to date share price performance and a much stronger 1 year total shareholder return of 55.8%. This...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rece-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rece-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4585","MDGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622589371","title":"Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2622589371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622589371?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:00","pubTimestamp":1774551615,"startTime":"0","endTime":"0","summary":"14:57 EDT Madrigal Pharmaceuticals (MDGL) off highs, remains up 13% in afternoon trading Published first on TheFly – the ultimate source for real-t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-off-highs-remains-up-13-in-afternoon-trading-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-off-highs-remains-up-13-in-afternoon-trading-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","MDGL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621570927","title":"Analysts’ Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621570927","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621570927?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:30","pubTimestamp":1774272637,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-madrigal-pharmaceuticals-mdgl-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-madrigal-pharmaceuticals-mdgl-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","MDGL","LU0128526141.USD","IDYA","BK4581","XBI","LU0029874061.USD","HCSG","LABU","XLV","BK4588","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620276114","title":"Madrigal Pharmaceuticals grants 1,739 inducement RSUs under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276114?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:05","pubTimestamp":1773950717,"startTime":"0","endTime":"0","summary":"Madrigal granted equity inducement awards to seven new non-executive employees under its 2025 Inducement Plan.The awards totaled 1,739 time-based restricted stock units.The restricted stock units vest in four equal installments on the first through fourth anniversaries of the grant date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6TqCbw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00B64PRP62.GBP","BK4139","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014039.USD","BK4588","NDAQ","SG9999014005.SGD","IE00BN0W2V16.EUR","MDGL","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617561306","title":"Madrigal Pharmaceuticals EVP and CFO Mardi Dier Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617561306","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617561306?lang=en_us&edition=fundamental","pubTime":"2026-03-07 08:19","pubTimestamp":1772842751,"startTime":"0","endTime":"0","summary":"Mardi Dier, EVP and CFO of Madrigal Pharmaceuticals Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260307:nNDLb7tbjL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Madrigal Pharmaceuticals EVP and CFO Mardi Dier Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617576880","title":"Madrigal Pharmaceuticals grants inducement equity awards to 20 new employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2617576880","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617576880?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:07","pubTimestamp":1772744863,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted equity inducement awards to 20 new non-executive employees under its 2025 Inducement Plan. The grants included options to purchase 789 shares at an exercise price of $432.00 per share and 6,882 time-based restricted stock units. The options vest 25% after one year and then 6.25% quarterly thereafter, while the restricted stock units vest in four equal annual installments over four years, subject to continued employment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL20P504:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","SG9999014021.USD","MDGL","IE00B3QW5Z07.USD","SG9999014039.USD","LU0314104364.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BGHQF748.EUR","NDAQ","SG9999014013.SGD","SG9999014005.SGD","LU2210150020.SGD","BK4588","BK4139","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613114817","title":"Madrigal Pharmaceuticals to Participate in TD Cowen 46th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613114817","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613114817?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:03","pubTimestamp":1771938232,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals to Participate in TD Cowen 46th Annual Health Care Conference               Madrigal Pharmaceuticals Inc. will participate in the TD Cowen 46th Annual Health Care Conference o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL2LT59g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014021.USD","BK4588","BK4112","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","BK4139","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014005.SGD","BK4585","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613773254","title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2613773254","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613773254?lang=en_us&edition=fundamental","pubTime":"2026-02-24 03:23","pubTimestamp":1771874584,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) is back in focus after reporting full-year 2025 results, combining nearly US$1 billion in Rezdiffra sales with a net loss of US$288.28 million and an improving per-share loss.\nSee our latest analysis for Madrigal Pharmaceuticals.\nThe recent full year 2025 update comes after a sharp pullback in the share price, with a 30 day share price return of 9.46% and a 90 day share price return of a 26.52% decline. However, longer term total shareholder returns of 35.04%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613220545","title":"Barclays Remains a Buy on Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613220545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613220545?lang=en_us&edition=fundamental","pubTime":"2026-02-22 20:16","pubTimestamp":1771762603,"startTime":"0","endTime":"0","summary":"Barclays analyst Eliana Merle maintained a Buy rating on Madrigal Pharmaceuticals on February 20 and set a price target of $964.00. The company’s s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4585","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612262527","title":"Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2612262527","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612262527?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:11","pubTimestamp":1771593060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2026 08:11 ET (13:11 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612226419","title":"Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2612226419","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612226419?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:26","pubTimestamp":1771590361,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $529 from $570 and keeps a Neutral rating on the shares. Following quart...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-lowered-to-529-from-570-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-lowered-to-529-from-570-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612223982","title":"Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2612223982","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612223982?lang=en_us&edition=fundamental","pubTime":"2026-02-20 06:15","pubTimestamp":1771539322,"startTime":"0","endTime":"0","summary":"Analyst Ritu Baral of TD Cowen maintained a Buy rating on Madrigal Pharmaceuticals, retaining the price target of $644.00. Ritu Baral has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/madrigal-pharmaceuticals-rezdiffras-strong-launch-expanding-prescriber-adoption-and-advancing-pipeline-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/madrigal-pharmaceuticals-rezdiffras-strong-launch-expanding-prescriber-adoption-and-advancing-pipeline-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129606368","title":"Stock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1129606368","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129606368?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:46","pubTimestamp":1771512378,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals' stock experienced a sharp decline in pre-market trading, plummeting 8.75% following the release of its fourth-quarter financial results.The biopharmaceutical company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":-0.0115},{"period":"1month","weight":0.1656},{"period":"3month","weight":0.0797},{"period":"6month","weight":0.2307},{"period":"1year","weight":0.6799},{"period":"ytd","weight":-0.1092}],"compareEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":0.0846},{"period":"3month","weight":0.0279},{"period":"6month","weight":0.0461},{"period":"1year","weight":0.3232},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.7,"avgChangeRate":0.060749},{"month":3,"riseRate":0.3,"avgChangeRate":-0.012858},{"month":4,"riseRate":0.5,"avgChangeRate":0.006856},{"month":5,"riseRate":0.333333,"avgChangeRate":0.130548},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032539},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.07894},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction